13d
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In a phase 1/2 trial, the IOL system lowered IOP at two ...
SpyGlass Pharma, Inc. (SGP) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information, although the final amount may differ. The biopharma is a ...
If you’re sick of sparse brows that are hard to shape, style or fix in place, it’s worth trying one of the best eyebrow serums. These potent products can strengthen hair, improve its condition and ...
Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during ...
Longer, darker lashes are having a moment. For those avoiding the risk or expense of lash extensions, serums can seem like a safer, more affordable option. But not all lash serums are created ...
(MENAFN- GlobeNewsWire - Nasdaq) ALISO VIEJO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SpyGlass PharmaTM, a late-stage biopharmaceutical company, today announced the appointment of Jean-Frédéric ...
SpyGlass Pharma, a late-stage biopharmaceutical company, announces positive results from two clinical trials of its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for ...
Amneal Pharmaceuticals (AMRX) just picked up a green light from the FDA for its bimatoprost ophthalmic solution 0.01%, the generic version of the well-known glaucoma treatment LUMIGAN. This FDA nod ...
(MENAFN- GlobeNewsWire - Nasdaq) Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal's Affordable Medicines segment BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE ...
BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company ...
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), a pharmaceutical company with a market capitalization of $3.14 billion and showing strong year-to-date returns of 26%, announced Tuesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results